Starton Therapeutics effectively continued to the US through creating a new Delaware Holdco to which its shareholders transferred directly or through exchangeable shares

Starton Therapeutics Inc., a BC corporation that is a clinical-stage biotechnology company, was the parent for the group. In order to effectively redomicile to the US without generating exit tax under ss. 128.1(4) and 219.1, a new Delaware corporation (the “Company”) was incorporated and the existing shareholders exchanged their shares on a taxable basis for shares of the Company, except that those electing for rollover treatment exchanged their shares under s. 85(1) for exchangeable shares of an indirect BC subsidiary of the Company which are held through a “CallCo” BC ULC direct subsidiary of the Company.

Neal Armstrong. Summary of S-1 of Starton Holdings, Inc. (the “Company”) under Other – Continuances/ Migrations – New Non-Resident Holdco.